Tenet Healthcare Corporation (NYSE:THC) went down by -4.09% from its latest closing price compared to the recent 1-year high of $39.37. The company’s stock price has collected -0.14% of loss in the last five trading sessions. Press Release reported on 09/09/20 that USPI Facilities Recognized for Excellence in Patient Experience
Is It Worth Investing in Tenet Healthcare Corporation (NYSE :THC) Right Now?
Tenet Healthcare Corporation (NYSE:THC) scored a price-to-earnings ratio above its average ratio, recording 12.78 x from its present earnings ratio. Plus, the 36-month beta value for THC is at 2.32. Opinions of the stock are interesting as 6 analysts out of 19 who provided ratings for Tenet Healthcare Corporation declared the stock was a “buy,” while 1 rated the stock as “overweight,” 12 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $30.65, which is $2.07 above the current price. THC currently public float of 103.52M and currently shorts hold a 7.72% ratio of that float. Today, the average trading volume of THC was 1.69M shares.
THC’s Market Performance
THC stocks went down by -0.14% for the week, with a monthly drop of -2.44% and a quarterly performance of 26.99%, while its annual performance rate touched 11.17%. The volatility ratio for the week stands at 4.47% while the volatility levels for the past 30 days are set at 4.91% for Tenet Healthcare Corporation. The simple moving average for the period of the last 20 days is -0.13% for THC stocks with a simple moving average of 9.26% for the last 200 days.
Analysts’ Opinion of THC
Many brokerage firms have already submitted their reports for THC stocks, with RBC Capital Mkts repeating the rating for THC by listing it as a “Outperform.” The predicted price for THC in the upcoming period, according to RBC Capital Mkts is $39 based on the research report published on March 11th of the current year 2020.
JP Morgan, on the other hand, stated in their research note that they expect to see THC reach a price target of $39. The rating they have provided for THC stocks is “Neutral” according to the report published on February 26th, 2020.
UBS gave a rating of “ Buy” to THC, setting the target price at $39 in the report published on December 9th of the previous year.
THC Trading at 9.39% from the 50-Day Moving Average
After a stumble in the market that brought THC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.94% of loss for the given period.
Volatility was left at 4.91%, however, over the last 30 days, the volatility rate increased by 4.47%, as shares sank -2.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +52.44% upper at present.
During the last 5 trading sessions, THC fell by -0.14%, which changed the moving average for the period of 200-days by -14.21% in comparison to the 20-day moving average, which settled at $28.37. In addition, Tenet Healthcare Corporation saw -25.40% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at THC starting from Fitzgerald Meghan, who bought 6,153 shares at the price of $13.02 back on Mar 17. After this action, Fitzgerald Meghan now owns 24,882 shares of Tenet Healthcare Corporation, valued at $80,112 using the latest closing price.
Sutaria Saumya, the President & COO of Tenet Healthcare Corporation, bought 20,000 shares at $17.28 during a trade that took place back on Mar 16, which means that Sutaria Saumya is holding 49,413 shares at $345,600 based on the most recent closing price.
Stock Fundamentals for THC
Current profitability levels for the company are sitting at:
- +9.09 for the present operating margin
- +9.09 for the gross margin
The net margin for Tenet Healthcare Corporation stands at -1.32. The total capital return value is set at 9.68, while invested capital returns managed to touch -1.64. Equity return is now at value 14.30, with -0.20 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 1.18, with the company’s debt to enterprise value settled at 0.72. The receivables turnover for the company is 5.99 and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.21.